Editorial: Sacubitril/valsartan in heart failure – a guide for primary care
Publication date: Monday, 21 November 2016
Contributor(s): Jan Procter-King, Mike Kirby
HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.